Does training family physicians in shared decision making promote optimal use of antibiotics for acute respiratory infections? Study protocol of a pilot clustered randomised controlled trial by Légaré, France et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Family Practice
Open Access Study protocol
Does training family physicians in shared decision making promote 
optimal use of antibiotics for acute respiratory infections? Study 
protocol of a pilot clustered randomised controlled trial
France Légaré*1,2, Michel Labrecque1,2, Annie LeBlanc1, Robert Thivierge3, 
Gaston Godin4, Claudine Laurier5, Luc Côté1,2, Annette M O'Connor6, 
Nadine Allain-Boulé1, Jean Rousseau1 and Sylvie Tapp1
Address: 1Research Centre of the Centre Hospitalier Universitaire de Québec, Québec, Canada, 2Department of Family Medicine, Université Laval, 
Québec, Canada, 3Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada, 4Faculty of Nursing, Pavillon Paul-Comtois, Université 
Laval, Québec, Canada, 5GRIS/Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada and 6Faculty of Health Sciences, School 
of Nursing, University of Ottawa, Ottawa, Canada
Email: France Légaré* - france.legare@mfa.ulaval.ca; Michel Labrecque - michel.labrecque@mfa.ulaval.ca; 
Annie LeBlanc - annie.leblanc.7@ulaval.ca; Robert Thivierge - robert.thivierge@umontreal.ca; Gaston Godin - gaston.godin@fsi.ulaval.ca; 
Claudine Laurier - claudine.laurier@umontreal.ca; Luc Côté - luc.cote@fmed.ulaval.ca; Annette M O'Connor - aoconnor@ohri.ca; 
Nadine Allain-Boulé - nadine.allain-boule@crsfa.ulaval.ca; Jean Rousseau - jean.rousseau@crsfa.ulaval.ca; 
Sylvie Tapp - sylvie.tapp@crsfa.ulaval.ca
* Corresponding author    
Abstract
Background: In North America, although it varies according to the specific type of acute respiratory infections
(ARI), use of antibiotics is estimated to be well above the expected prevalence of bacterial infections. The
objective of this pilot clustered randomized controlled trial (RCT) is to assess the feasibility of a larger clustered
RCT aiming at evaluating the impact of DECISION+, a continuing professional development (CPD) program in
shared decision making, on the optimal use of antibiotics in the context of ARI.
Methods/design: This pilot study is a cluster RCT conducted with family physicians from Family Medicine
Groups (FMG) in the Quebec City area, Canada. Participating FMG are randomised to an immediate DECISION+
group, a CPD program in shared decision making, (experimental group), or a delayed DECISION+ group (control
group). Data collection involves recruiting five patients consulting for ARI per physician from both study groups
before (Phase 1) and after (Phase 2) exposure of the experimental group to the DECISION+ program, and after
exposure of the control group to the DECISION+ program (Phase 3). The primary outcome measures to assess
the feasibility of a larger RCT include: 1) proportion of contacted FMG that agree to participate; 2) proportion
of recruited physicians who participate in the DECISION+ program; 3) level of satisfaction of physicians regarding
DECISION+; and 4) proportion of missing data in each data collection phase. Levels of agreement of the patient-
physician dyad on the Decisional Conflict Scale and physicians' prescription profile for ARI are performed as
secondary outcome measures.
Discussion: This study protocol is informative for researchers and clinicians interested in designing and/or
conducting clustered RCT with FMG regarding training of physicians in shared decision making.
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Background
Most health decisions occur in context of scientific uncer-
tainty, the "grey zone" of decision making, and making
decisions about the use of antibiotics for acute respiratory
infections (ARI) is no exception [1]. ARI are the most fre-
quently reported reasons for consulting a primary care
provider in North America and include acute otitis media,
acute rhinosinusitis, acute pharyngitis, and acute bronchi-
tis. Together, these infections, excluding pharyngitis but
including chronic sinusitis and eustachian tube disorders
account for 5.7% of the primary diagnosis groups for
adults and reach a total of 16.3% for children under the
age of twelve in community based practices [2]. Although
each type of ARI has distinct features, they all share in
common that a large proportion of those infections are
viral. Indeed, only 38% of adults with rhinosinusitis, 6%
to 18% of children with ARI, and 5 to 15% of adults with
pharyngitis have a bacterial infection [3,4]. Nonetheless
in North America, although it varies according to the spe-
cific type of ARI [5-13], the use of antibiotic is estimated
to be 63% to 67%, well above the expected prevalence of
bacterial infections [5,7-11,14-17].
As suggested above, diagnostic and management of ARI
are ripped with uncertainty. The probabilistic nature of
the diagnosis of ARI makes it difficult for both the physi-
cian and the patient to choose the "best" course of action
and is associated with prescription of antibiotics [18]. Sci-
entific evidence that imparts conflicting results regarding
treatment options (i.e. balance between risks and bene-
fits) or the absence or insufficiency of scientific evidence
makes this choice even more difficult [19]. Moreover, the
probabilistic aspect of the evidence that is drawn from
populations implies uncertain outcomes for the individ-
ual [20]. Consequently, patients and physicians need help
in addressing their decisional needs and in resolving
uncertainty when making decisions about the use of anti-
biotics for ARI, the most frequent "grey zone" health deci-
sions in primary care.
Shared decision making (SDM) is a promising strategy for
effective knowledge translation (KT) between health pro-
viders and their patients, particularly so in contexts of
"grey-zone" decisions [21]. SDM refers to a process by
which a healthcare choice is made by practitioners
together with the patient, based on the best available evi-
dence and in line with what an informed patient would
value. If indeed "Knowledge translation is the exchange,
synthesis and ethically-sound application of knowledge –
within a complex system of interactions", then conceptu-
alizing and operationalizing it as an interactive and
dynamic process between patients and health providers
has important consequences. It may foster a new breed of
more effective KT interventions in clinical contexts [22].
However, it is not clear how SDM can be implemented in
clinical practice. Given that most current efforts in KT deal
with the implementation of clinical practice guidelines
(CPG) where recommendations are considered as rules to
be followed, it is not clear if the implementation processes
of SDM and CPG are compatible. The proposed study
addresses the urgent need to reconcile the current KT
endeavours with the need to determine effective ways by
which patients are engaged to share their preferences and
participate in the process to achieve "grey zone" decisions.
In other words, it lays the grounds for a new KT model at
the clinical level: the SDM model.
We are planning a large clustered randomized clinical trial
(RCT) aiming at evaluating the impact of DECISION+, a
continuing professional development program in shared
decision making on the optimal use of antibiotics for
treating ARI. We report on the study protocol of an ongo-
ing pilot clustered randomized controlled trial (RCT) to
assess the feasibility of this larger trial. Based on our con-
ceptual framework (Figure 1), specific aims include to: 1)
assess the feasibility of recruiting Family Medicine Groups
(FMG), family physicians/general practitioners (FPs/GPs)
and their patients, 2) develop, adapt and validate DECI-
SION+ training workshops and related material, and 3)
evaluate physicians' participation and satisfaction regard-
ing DECISION+. Specific aims also include estimating the
impact of DECISION+ on: 1) decision of both physicians
and their patients regarding the use of antibiotics, 2) deci-
sional conflict scores of both physicians and their patients
as well as level of agreement between their decisional con-
flict scores, 3) prescription profile of antibiotics for ARI,
4) intention of physicians to implement SDM in their
clinical practice, 5) intention of physicians to implement
clinical practice guidelines on ARI, 6) scores obtained by
physicians on a Script Concordance Test (SCT), and 7)
decisional regret of patients.
Methods/Design
Design
The study is a two-arm clustered RCT conducted in the
Quebec City area, Canada (Figure 2). FMG is the unit of
randomisation. A FMG consists in a group of family phy-
sicians who work in close cooperation with nurses to offer
family medicine services to registered individuals. There
are currently over 130 such groups in the Province of Que-
bec. FMG are randomized to either 1) an immediate
DECISION+ program (experimental group) or 2) a
delayed DECISION+ program (control group). Simple
randomisation and concealed assignment is performed by
an independent biostatistician using Internet-based soft-
ware.BMC Family Practice 2007, 8:65 http://www.biomedcentral.com/1471-2296/8/65
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Participants
Physicians
FPs/GPs are the main target participants and are recruited
through FMG. A random list of all FMG in the Quebec
City area was generated. Based on that list and in
sequence, each physician who is in charge of the FMG is
contacted by phone by one of the two co-principal inves-
tigators (FL or ML). If the contacted FMG includes at least
10 physicians, the study protocol is explained to the phy-
sician in charge and willingness to organise a meeting
with colleagues from his/her group to further explain the
nature of the project is sought.
FPs/GPs are not eligible to participate if they are currently
participating or have previously participated to an imple-
mentation study of SDM in clinical practice. They are also
excluded if they do not plan to be in clinical practice for
the whole duration of the study (e.g. pregnancy, retire-
ment, practice restricted exclusively to administrative
duties). A FMG is not eligible if less than six eligible phy-
sicians agree to participate in the study. Reasons for exclu-
sion or refusal to participate after the first telephone
contact or after the face-to-face meeting are documented.
Patients
Patients are included if they meet the following criteria: a)
adults or children consulting a participating physician for
ARI, b) antibiotic treatment considered by the patient
himself (or guardian) or by the physician, c) able (adults
or guardians) to read, understand, and write French
(equivalent to grade 8), and d) able to give informed con-
sent (adults or guardians). Patients with a condition
requiring emergency care are excluded. All participants,
FPs/GPs and patients, sign an informed consent form
approved by the ethics committee from the research insti-
tution.
Interventions
DECISION+ is a multifaceted CDP program offered over
a 4- to 6-month period and includes the following:
Decision+ Conceptual Framework Figure 1
Decision+ Conceptual Framework.BMC Family Practice 2007, 8:65 http://www.biomedcentral.com/1471-2296/8/65
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Interactive workshops
Three 180-minute workshops are offered to participating
FPs/GPs. Each one addresses a key component of our con-
ceptual framework (Figure 1). The first workshop focuses
on the probabilistic nature of the diagnosis of a bacterial
vs. viral ARI. The second workshop focuses on the availa-
ble evidence regarding the balance between risks and ben-
efits when facing decision about the use antibiotics or not
in ARI. It also addresses effective strategies to communi-
cate this information to a patient. The third workshop
focuses on strategies to foster active participation of
patients in the decision-making process.
All three workshops include videos that facilitate group
discussion about perceived barriers and facilitators to
implementing SDM in the context of the use antibiotics
for ARI. All workshops are offered at the FMG clinical site
and leaded by experienced trainers (co-PI and co-I). Par-
ticipants receive a toolkit including the material from the
training workshops and a series of decision support tools
to help them communicate with their patients the proba-
bility of a bacterial vs. viral ARI and the risks and benefits
associated with the use of antibiotic in ARI. These decision
support tools also include a section to help clarify
patient's values regarding the use of antibiotics in ARI. All
workshops are audio-taped to ensure fidelity of the inter-
vention across FMG.
Reminders of expected behaviours
After completion of a given workshop, participating phy-
sicians receive reminders of the expected behaviours on a
regular basis. The reminders summarize and emphasize
the key elements of the workshops.
Feedback
Results of score agreement on the Decisional Conflict
Scale between patients and physicians, as measured dur-
ing the patient recruitment periods before the first work-
shop (Phase 1 in the experimental group and Phase 1 and
2 in the control group – see Figure 2), are provided to par-
Decision+ Trial Design Figure 2
Decision+ Trial Design.
Patient recruitment Phase 2 
(5 Pts/physician)
Immediate DECISION+ Program
Recruitment of Family Medicine Groups
Randomization
• Baseline questionnaires  
• Patient recruitment Phase 1 
(5 Pts/physician)
Delayed DECISION+ Program
Patient recruitment Phase 2
(5 Pts/physician)
Duration
• Script Concordance Test 1
• Workshops (3 X 180 minutes)
• Script Concordance Test 2 
• Reminders + Feedback
2-3 months 
4-6 months
4-6 months
RCT Analysis
(Decision+ group vs. 
no Decision+ group)
• Baseline questionnaires  
• Patient recruitment Phase 1 
(5 Pts/physician)
Before-After Analysis
(Immediate + Delayed 
DECISION+ groups 
combined)
 Patient recruitment Phase 3
(5 Pts/physician)
• Exit questionnaires
• Script Concordance Test 2
• Workshops (3 X 180 minutes) 
• Script Concordance Test 3
• Reminders + Feedback
• Patient recruitment Phase 3
(5 Pts/physician)
• Exit questionnaires
2-3 months
2-3 months
Script Concordance Test 3
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ticipating FPs/GPs in a personalized sealed envelope at
the beginning of the third workshop. Physicians are also
provided with pooled results from their colleagues. Time
is provided during the workshop to explain how to inter-
pret the results and for group discussion. A personalized
and group prescription profile related to antibiotic pre-
scribed to patients consulting with ARI is provided at the
end of the series of workshops.
Primary outcome measures
Primary outcome measures intend to assess the feasibility
of a larger RCT aiming at evaluating the impact of the
DECISION+ program. They include: a) proportion of con-
tacted FMG that agree to participate, 2) proportion of
recruited FPs/GPs that participate in the DECISION+ pro-
gram, 3) level of satisfaction of FPs/GPs regarding DECI-
SION+, and 4) proportion of missing data in each data
collection phase. The subsequent RCT will be considered
feasible if: 1) the proportion of contacted FMG that partic-
ipate to the pilot study is 50% or greater, 2) the propor-
tion of recruited physicians who participate in all three
workshops is 70% or greater, 3) the mean level of satisfac-
tion regarding the workshops is 65% or greater, and 4) the
proportion of missing data in each completed question-
naire is less than 10%.
Secondary outcome measures
Secondary outcomes measures aim at exploring the
impact of the DECISION+ program on the decision mak-
ing processes and the optimal use of antibiotics in the
context of ARI. These measures include:
Decision to use antibiotics
After each clinical encounter for ARI, both patients and
their FPs/GPs indicate if it was decided to: 1) use antibiot-
ics, 2) delay antibiotics or 3) not use antibiotics.
Decisional conflict
After each clinical encounter for ARI, both patients and
physicians complete the Decision Conflict Scale. This
scale includes 16 items, each item being scored on a 5-
point Likert scale (1 = strongly agree to 5 = strongly disa-
gree) with higher score associated with higher decisional
conflict. Internal consistency coefficients (Cronbach's
alpha) from previous studies ranged from 0.78 to 0.92 in
the patients' version and from 0.78 to 0.90 in the physi-
cians' version [23,24].
Decisional regret
One to two weeks after clinical encounter, patients com-
plete the Decisional Regret Scale over the phone (Cron-
bach's alpha = 0.81 to 0.92 in previous studies) [25].
Prescription profile of antibiotics in ARI
Prescription profile of all FPs/GPs from the Quebec City
area, including all physicians participating in the study, is
established using the Régie de l'Assurance Maladie du
Québec (RAMQ) databases. Data are restricted to patients
covered by the public prescription drug insurance of the
Province of Quebec (about half of the total population in
the province). Type of antibiotics prescribed and date of
prescription filling are matched with the reasons for
encounter (for an ARI) as stated by physicians for billing
purpose. Data collection extends from 3 months before
the beginning of the study to 3 months after the end of the
study.
Script Concordance Test (SCT)
Clinical reasoning is assessed with a SCT on diagnosis and
management of ARI [26-31]. The same SCT is completed
three times over the study period (Figure 2). In both
groups, SCT are completed at the beginning of the first
and at the end of the third workshop (SCT 1 and 2 in the
experimental group and SCT 2 and 3 in the control
group). SCT 1 in the control group is completed at base-
line and SCT 3 in the experimental group at exit of the
study.
Physicians' reactions to uncertainty
Two subscales from the Physicians' Reactions to Uncer-
tainty questionnaire are completed at baseline: anxiety
about uncertainty and disclosing uncertainty to patients
[32,33].
Intention to engage in SDM and to use clinical practice guidelines 
regarding the use of antibiotics in ARI in future clinical encounters
At baseline, in reference to the theory of planned behav-
iour [34], FPs/GPs complete a questionnaire assessing
their attitude, subjective norm, perceived behavioural
control, and intention to engage in SDM as well as to use
clinical practice guidelines in future clinical encounters
dealing with the use of antibiotics in ARI. Physicians are
also asked to complete this questionnaire at the exit of the
study.
Before their clinical encounter for ARI, each participating
patient is asked to complete a similar questionnaire on
intention to engage in SDM in a clinical encounter dealing
with the use of antibiotics in ARI.
Data collection process
Data on FPs/GPs' socio-demographic characteristics,
intention to integrate SDM and clinical practice guidelines
on ARI in practice, and reaction to uncertainty are col-
lected at baseline in both groups (Figure 2). Then, five
patients consulting a participating physician for an ARI
are recruited by a research assistant in the waiting room
before the clinical encounter (Phase 1). Data on patients'BMC Family Practice 2007, 8:65 http://www.biomedcentral.com/1471-2296/8/65
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socio-demographic characteristics and intention to
engage in SDM when consulting for an ARI are collected
at that point in time. FPs/GPs and patients are both
invited to complete the Decisional Conflict Scale after the
clinical encounter. Patients and FPs/GPs are blinded to
the answers of the other member of the dyad. Patient
recruitment and completion of the Decisional Conflict
Scale by patient and physician are repeated at two weeks
after the third workshop of the immediate DECISION+
group (Phase 2) and again after the third workshop of the
delayed DECISION+ group (Phase 3). All patients are
contacted by phone one to two weeks after their clinical
encounter to complete the Decisional Regret Scale.
Finally, all participating FPs/GPs complete an exit ques-
tionnaire including data on intention to engage in SDM
and use of clinical practice guideline as well as on satisfac-
tion with the DECISION+ program.
Sample size and analysis
The objective is to recruit four FMG (at least 24 physicians
and a total of 360 patients with an ARI that is 5 patients
per physician in each one of the three recruitment phases)
for this pilot clustered RCT. This study is a feasibility study
and therefore no sample size calculation was performed.
Our design allow a comparison of physicians (and
patients) data randomly exposed or not to the DECI-
SION+ program (RCT) and a comparison of before and
after data combining the results of the immediate and
delayed exposure to the DECISION+ program.
It is not possible to blind participating FPs/GPs from the
planned intervention but individuals involved with data
analyses will be blinded to group allocation and initial
results will be provided to researchers without revealing
group allocation. Statistical analysis for the primary out-
come feasibility measures will be performed using pro-
portions and means and associated 95% confidence
intervals. Methods for assessing the statistical significance
of the secondary outcome measures between study groups
will take into account the clustered nature of the dataset.
Discussion
This study protocol is informative for researchers and cli-
nicians interested in designing and/or conducting clus-
tered RCT regarding training of family physicians in
shared decision making. In line with our previous work
[35,36], this pilot clustered RCT is highly relevant to fam-
ily medicine as ARI are the most frequently reported rea-
sons for consulting a primary care provider in North
America and the use of antibiotics for ARI appears to be
suboptimal. Although this is a pilot project, the delivera-
bles are many and important as they will: 1) provide inno-
vative insight on how to successfully implement change in
clinical practices using a SDM perspective, 2) be helpful
for future research on new models of collaborative care
within the workforce environment in primary care, 3)
serve as a strategy to increase quality of care and patient
safety, and 4) reinforce a patient-centered care approach,
one that highly values relationships and a shared under-
standing by patients and their FPs/GPs of the nature of the
problem that is being addressed, the available options,
and the role of both patient and provider to the decision
making process [37].
In summary, this is the first study to assess the impact of
DECISION+, a multifaceted CDP program that fosters
SDM during primary care clinical encounters dealing with
the decision to use antibiotics or not in ARI. Its results will
lay the grounds for the implementation of SDM in family
medicine. The expected results from this project should
guarantee the feasibility of a larger clustered RCT aiming
at evaluating the impact of DECISION+ on the optimal
use of antibiotics use in ARI.
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